|
Indications and Dosage
Intramuscular
Active immunisation against diphtheria, tetanus, pertussis and Haemophilus influenza Child: ≥2 months to <6 years As primary immunisation: 3 doses of 0.5 mL via deep inj into the anterolateral muscles of the thigh or the deltoid muscles of the upper arm with 2-month intervals. Booster dose: 0.5 mL approx 6-12 months after last dose. Refer to literature as dosage may vary with brand and local guidelines.
|
|
Contraindications
Hypersensitivity. History of encephalopathy within 7 days with pertussis vaccine. Progressive neurological disorder (e.g. infantile spasms, uncontrolled epilepsy, or progressive encephalopathy).
|
|
Special Precautions
Patient with family history of seizures; personal history of Guillain-Barre syndrome within 6 weeks of tetanus vaccine, ≥40.5°C temperature, hypotonic-hyporesponsive episode or crying for ≥3 hours within 48 hours or seizures within 3 days of pertussis vaccine; immunosuppression, severe febrile illness, bleeding disorder, thrombocytopenia. Postpone vaccination in patients with acute infection or severe febrile illness.
|
|
Adverse Reactions
Significant: Fever (≥40.5°C temperature), hypotonic-hyporesponsive episode, inconsolable crying, irritability, seizures; oedematous reactions with erythema, purpura, cyanosis; syncope, Guillain-Barre syndrome, brachial neuritis.
Gastrointestinal disorders: Vomiting, diarrhoea, nausea. General disorders and administration site conditions: Malaise, inj site reactions (e.g. tenderness, pain, oedema, erythema). Metabolism and nutrition disorders: Appetite loss. Nervous system disorders: Somnolence. Psychiatric disorders: Restlessness, nervousness. Skin and subcutaneous tissue disorders: Erythema, rash, pruritus. Vascular disorders: Pallor. Potentially Fatal: Hypersensitivity or anaphylaxis reactions. |
|
Monitoring Parameters
Monitor for signs of anaphylaxis and syncope for 15 minutes after injection.
|
|
Drug Interactions
Decrease effect with immunosuppressive agents (e.g. corticosteroids, antimetabolites).
|
|
Lab Interference
May interfere with urine antigen detection for Haemophilus influenzae type b infection for 2 weeks.
|
|
Action
Description:
Mechanism of Action: DTP-HIB vaccine, a combined vaccine of adsorbed diphtheria, tetanus toxoids, acellular pertussis and of Haemophilus influenzae type b conjugate vaccines, promotes immunity against diphtheria, tetanus, pertussis and Haemophilus influenzae type b infections. |
|
Storage
Store between 2-8°C. Do not freeze.
|
|
MIMS Class
|
|
References
Anon. Diphtheria, Tetanus Toxoids and Acellular Pertussis Vaccine and Haemophilus influenzae b Conjugate Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 16/07/2018. Buckingham R (ed). Diphtheria, Tetanus, Pertussis and Haemophilus Influenzae Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/07/2018. Buckingham R (ed). Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 16/07/2018.
|
Sign Out
